What do systematic reviews say?

RISPERIDONE vs placebo

RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).

• Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.69 [0.62, 0.78]
  12 studies · 2261 participants
  Low

RISPERIDONE DEPOT vs RISPERIDONE

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 1.28 [0.92, 1.79]
  2 studies · 690 participants
  Moderate

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

• Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
  1.13 [0.53, 2.42]
  3 studies · 167 participants
  Very low

RISPERIDONE DEPOT vs placebo

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ all doses risperidone depot ‐… compared with PLACEBO (very low certainty).

• Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
  RR 0.74 [0.63, 0.88]
  1 study · 400 participants
  Very low

RISPERIDONE vs CLOZAPINE ‐ all data short term

It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).

• Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
  RR 0.49 [0.1, 2.51]
  2 studies · 45 participants
  Very low

RISPERIDONE vs QUETIAPINE

RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).

• Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
  RR 0.96 [0.86, 1.07]
  1 study · 294 participants
  Low